<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537078</url>
  </required_header>
  <id_info>
    <org_study_id>0201350</org_study_id>
    <nct_id>NCT04537078</nct_id>
  </id_info>
  <brief_title>Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders</brief_title>
  <official_title>Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>El Shatby University Hospital for Obstetrics and Gynecology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>El Shatby University Hospital for Obstetrics and Gynecology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The worldwide prevalence of primary and secondary infertility is estimated at ~2% and 10.5%,&#xD;
      respectively, among women aged 20-44 years and attempting to conceive. These women may enter&#xD;
      an IVF program and be classified as poor prognosis patients for several distinct causes (e.g.&#xD;
      advanced maternal age, low ovarian reserve). proper tailoring of the ovarian stimulation&#xD;
      protocol to maximize the number of oocytes collected represents a crucial step for them to&#xD;
      eventually conceive .&#xD;
&#xD;
      Recent evidence indicates that in the same menstrual cycle, there are multiple follicular&#xD;
      recruitment waves. This is in accord with the theory that folliculogenesis occurs in a&#xD;
      wave-like fashion. Thus, within a single menstrual cycle, there can theoretically be multiple&#xD;
      opportunities for a clinician to collect oocytes, as opposed to the conventional single&#xD;
      cohort of antral follicles during the follicular phase .&#xD;
&#xD;
      Utilizing this concept, reproductive endocrinologists have been attempting to retrieve&#xD;
      oocytes from poor responders using both the follicular-phase stimulation (FPS) and the&#xD;
      luteal-phase stimulation (LPS) protocols in order to increase the number of oocytes collected&#xD;
      shorter period of time. The number of oocytes collected in IVF is a robust surrogate outcome&#xD;
      for clinical success since there is a clear relationship between the number of oocytes&#xD;
      collected and live birth rates across all female age groups.&#xD;
&#xD;
      which protocol is the most effective remains controversial and the efficacy of PPOS in POR&#xD;
      compared with that of conventional protocols is unclear.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted on 80 infertile women indicated for ICSI with criteria of poor&#xD;
      ovarian response defined by Bologna criteria(15) All participants will be informed about the&#xD;
      nature of the study and informed consent will be taken from all of them.&#xD;
&#xD;
      Group 1:40 patients will be given the progestin primed double stimulation protocol.&#xD;
&#xD;
      Group 2: 40 patients will be given the flexible GnRh antagonist follicular controlled ovarian&#xD;
      stimulations will be done in 2 cycles.&#xD;
&#xD;
      Written informed consents will be obtained from all participants who accept to participate in&#xD;
      the research protocol.&#xD;
&#xD;
      Work up:&#xD;
&#xD;
        1. Complete history taking and full assessment of different infertility factors.&#xD;
&#xD;
        2. Hormonal investigations&#xD;
&#xD;
             -  FSH, LH, E2, Prolactin&#xD;
&#xD;
             -  AMH, TSH&#xD;
&#xD;
        3. Basal transvaginal ultrasound&#xD;
&#xD;
      Clinical and embryological procedures:&#xD;
&#xD;
      Group 1:&#xD;
&#xD;
      I. The follicular phase of the double stimulation protocol&#xD;
&#xD;
        1. luteal phase priming using combined contraceptive pills from day 21 of the previous&#xD;
           cycle for one week (0.03 mg ethinyl estradiol, gestodene 0.075 mg, Gynera tab, Bayer&#xD;
           Pharma AG., Berlin, Germany).&#xD;
&#xD;
        2. Controlled ovarian hyper-stimulation with 225-375 IU of gonadotropins will be started&#xD;
           day 2-3 of menses after vaginal ultrasound confirming the absence of ovarian cysts.&#xD;
&#xD;
        3. Dydrogesterone (Duphaston, Abbott company, Illinois, United states) at 20 mg/day will be&#xD;
           started from the first day of the ovulation induction.&#xD;
&#xD;
        4. Patient response will be monitored by:&#xD;
&#xD;
             1. Transvaginal follicular scanning and the dose of the gonadotropins will be modified&#xD;
                according to the response.&#xD;
&#xD;
             2. Serum estradiol.&#xD;
&#xD;
             3. Serum progesterone and LH on the day of triggering.&#xD;
&#xD;
        5. GnRh agonist triggering (Decapeptyl, Ferring, SAINT-PREX Switzerland) in a dose of 2&#xD;
           ampules of 0.2 mg will be administered when leading follicle &gt;18 mm in diameter.&#xD;
&#xD;
        6. Oocyte pickup will be done 36 hours after GnRh administration with precaution of leaving&#xD;
           the follicles measuring 11 mm or less.&#xD;
&#xD;
        7. After the pick-up, oocytes will be denuded. The denuded oocytes are then assessed for&#xD;
           nuclear status. Mature oocytes will be used for ICSI.&#xD;
&#xD;
      II. The luteal phase of the double stimulation protocol&#xD;
&#xD;
      Controlled ovarian hyper-stimulation with 225-375 IU of gonadotropins will be started the&#xD;
      next day after the previous oocyte pickup simultaneously with Dydrogesterone (Duphaston,&#xD;
      Abbott company, Illinois, United states) at 20 mg/day.&#xD;
&#xD;
      The rest will be as the follicular phase.&#xD;
&#xD;
      III. Fertilization and embryo quality:&#xD;
&#xD;
      The fertilization check, which will be performed 16 to 20 hours after ICSI. The resultant&#xD;
      embryos will be scored, and they will be vitrified for subsequent transfer.&#xD;
&#xD;
      IV. Embryo transfer&#xD;
&#xD;
      - Starting from the next menstrual cycle Day 3, patients will receive oral estradiol valerate&#xD;
      (Cyclo-Progynova (white tablets); Bayer, Germany) daily. From Day 10 onwards, endometrium&#xD;
      growth will be monitored by transvaginal ultrasound. When endometrial thickness â‰¥ 7 mm.&#xD;
      Progesterone administration (as 800 mg/day vaginal suppositories per day and 100 mg ampule IM&#xD;
      every other day) will be initiated and Embryo transfer will be scheduled on Day 3, 4 or 5&#xD;
      with maximum number of 3 class A embryos whether of cleavage or blastocyst stage.&#xD;
&#xD;
      V. Luteal support - Progesterone administration (as 800 mg/day vaginal suppositories per day&#xD;
      and 100 mg ampule IM every other day) will be continued until pregnancy testing 18 days after&#xD;
      embryo transfer. The pregnant cases will continue the luteal support till the 12 weeks of&#xD;
      gestation.&#xD;
&#xD;
      Group 2:&#xD;
&#xD;
      VI. The flexible GnRH antagonist protocol controlled ovarian stimulation This controlled&#xD;
      ovarian stimulation will be done twice in two different cycles&#xD;
&#xD;
      In each cycle:&#xD;
&#xD;
        1. luteal phase priming using combined contraceptive pills from day 21 of the previous&#xD;
           cycle for one week (0.03 mg ethinyl estradiol, gestodene 0.075 mg , Gynera tab, Bayer&#xD;
           Pharma AG., Berlin, Germany).&#xD;
&#xD;
        2. Controlled ovarian hyper-stimulation using antagonist protocol will be used. Stimulation&#xD;
           with 225-375 IU of gonadotropins will be started day 2-3 of menses after vaginal&#xD;
           ultrasound confirming the absence of ovarian cysts.&#xD;
&#xD;
        3. GnRH antagonist ( Cetrotide , Merck Serono, Darmstadt, Germany) will be given daily as&#xD;
           the biggest oocyte reaches size 14 mm.&#xD;
&#xD;
        4. Patient response will be monitored by:&#xD;
&#xD;
             1. Transvaginal follicular scanning and the dose of the gonadotropins will be modified&#xD;
                according to the response.&#xD;
&#xD;
             2. Serum estradiol.&#xD;
&#xD;
             3. Serum progesterone on the day of triggering.&#xD;
&#xD;
        5. GnRh agonist triggering (Decapeptyl, Ferring, Saint-Prex Switzerland) in a dose of 2&#xD;
           ampules 0.2 mg will be administered when leading follicle &gt;18 mm in diameter. While in&#xD;
           the second cycle HCG triggering (Choriomon, IBSA, Lugano, Switzerland) in a dose of&#xD;
           10,000 IU will be administered when the leading follicle &gt;18 mm in diameter.&#xD;
&#xD;
        6. Oocyte pickup will be done 36 hours after GnRh administration.&#xD;
&#xD;
        7. After the pick-up, oocytes will be denuded. The denuded oocytes are then assessed for&#xD;
           nuclear status. Mature oocytes will be used for ICSI.&#xD;
&#xD;
      VII. Fertilization and embryo quality:&#xD;
&#xD;
      The fertilization check, which will be performed 16 to 20 hours after ICSI. The resultant&#xD;
      embryos will be scored.&#xD;
&#xD;
      Embryos of the first cycle will be vitrified while embryos of the second cycle will be&#xD;
      freshly transferred unless there is excess for vitrification for subsequent trials of&#xD;
      transfer.&#xD;
&#xD;
      VIII. Embryo transfer&#xD;
&#xD;
      - Progesterone administration (as 800 mg/day vaginal suppositories per day and 100 mg ampule&#xD;
      IM every other day) will be initiated on the day of the oocyte pick up of the second cycle.&#xD;
      Embryo transfer will be scheduled on Day 3, 4 or 5 with maximum number of 3 class A embryos&#xD;
      whether of cleavage or blastocyst stage that will be a mixture of the thawed embryos of the&#xD;
      first cycle and fresh embryos of the second cycle.&#xD;
&#xD;
      IX. Luteal support Progesterone administration (as 800 mg/day vaginal suppositories per day&#xD;
      and 100 mg ampule IM every other day) will be continued until pregnancy testing 18 days after&#xD;
      embryo transfer. The pregnant cases will continue the luteal support till the 12 weeks of&#xD;
      gestation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the number of M2 oocytes retrieved</measure>
    <time_frame>within one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the fertilization rate</measure>
    <time_frame>within one year</time_frame>
    <description>percentage transformation of micro injected oocytes into two pronuclei</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the implantation rate</measure>
    <time_frame>within one year</time_frame>
    <description>the percentage of embryos which successfully undergo implantation compared to the number of embryos transferred in a given period. In practice, it is generally calculated as the number of intrauterine gestational sacs observed by transvaginal ultrasonography divided by the number of transferred embryos</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the clinical pregnancy rate.</measure>
    <time_frame>within one year</time_frame>
    <description>percentage of cases in which observation of a gestational sac with fetal heart beat by transvaginal ultrasound at 6 weeks of pregnancy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessing the difference in the ongoing pregnancy rate in both protocols.</measure>
    <time_frame>within one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing the difference between the follicular phase and the luteal phase of the progestin primed double stimulation protocol regarding the number of M2 oocytes retrieved and the fertilization rate.</measure>
    <time_frame>within one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing the difference between the follicular phase of the progestin primed double stimulation protocol and the first round of the conventional GnRH antagonist protocol regarding the number of M2 oocytes retrieved and the fertilization rate.</measure>
    <time_frame>within one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost analysis of both protocols.</measure>
    <time_frame>within one year</time_frame>
    <description>comparing financial cost of both protocols</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>the progestin primed double stimulation group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>luteal phase priming using combined contraceptive pills from day 21 of the previous cycle for one week by Gynera tab. Controlled ovarian hyper-stimulation with 225-375 IU of gonadotropins will be started day 2-3 of menses after vaginal ultrasound confirming the absence of ovarian cysts. Duphastonat 20 mg/day will be started from the first day of the ovulation induction.Decapeptyl in a dose of 2 ampules of 0.2 mg will be administered when leading follicle &gt;18 mm in diameter for triggering.Then, Controlled ovarian hyper-stimulation the next day after the previous oocyte pickup simultaneously with Duphaston. Starting from the next menstrual cycle Day 3, patients will receive oral estradiol valerate (Cyclo-Progynova (white tablets) daily.When endometrial thickness â‰¥ 7 mm.Embryo transfer will be scheduled on Day 3, 4 or 5 with maximum number of 3 class A embryos whether of cleavage or blastocyst stage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the flexible GnRh antagonist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This step will be done twice in two different cycles In each cycle: luteal phase priming using combined contraceptive pills from day 21 of the previous cycle for one week by Gynera tab. Controlled ovarian hyper-stimulation using antagonist protocol will be used. Stimulation with 225-375 IU of gonadotropins will be started day 2-3 of menses after vaginal ultrasound confirming the absence of ovarian cysts. Cetrotide ampule will be given daily as the biggest oocyte reaches size 14 mm. Decapeptyl ampules 0.2 mg will be administered when leading follicle &gt;18 mm in diameter. While in the second cycle HCG triggering (Choriomon)in a dose of 10,000 IU will be administered when the leading follicle &gt;18 mm in diameter. Embryo transfer will be scheduled on Day 3, 4 or 5 with maximum number of 3 class A embryos whether of cleavage or blastocyst stage that will be a mixture of the thawed embryos of the first cycle and fresh embryos of the second cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duphaston</intervention_name>
    <description>will be used for pituitary suppression in the first arm:20 mg/day will be started from the first day of the ovulation induction in the follicular phase and in the luteal phase will be started the next day after oocyte pickup at 20 mg/day.</description>
    <arm_group_label>the progestin primed double stimulation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonadotropin</intervention_name>
    <description>will be used for controlled ovarian hyperstimulation in both arms</description>
    <arm_group_label>the flexible GnRh antagonist</arm_group_label>
    <arm_group_label>the progestin primed double stimulation group</arm_group_label>
    <other_name>Fostimon</other_name>
    <other_name>Menopure</other_name>
    <other_name>Menogon</other_name>
    <other_name>Gonapure</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetrotide Injectable Product</intervention_name>
    <description>will used in the second arm for pituitary suppression in the second group daily when the biggest oocyte reaches size 14 mm till ovulation triggering</description>
    <arm_group_label>the flexible GnRh antagonist</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decapeptyl</intervention_name>
    <description>will be used for ovulation triggering.in the first arm:in a dose of 2 ampules of 0.2 mg will be administered when leading follicle &gt;18 mm in diameter. in the second arm:in a dose of 2 ampules 0.2 mg will be administered when leading follicle &gt;18 mm in diameter in the first cycle only.</description>
    <arm_group_label>the flexible GnRh antagonist</arm_group_label>
    <arm_group_label>the progestin primed double stimulation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chorionic Gonadotropin</intervention_name>
    <description>will be used in the second cycle of the second arm for ovulation triggering in a dose of 10,000 IU when the leading follicle &gt;18 mm in diameter.</description>
    <arm_group_label>the flexible GnRh antagonist</arm_group_label>
    <other_name>choriomon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combined Oral Contraceptive</intervention_name>
    <description>luteal phase priming from day 21 of the cycle before controlled ovarian stimulation for one week .</description>
    <arm_group_label>the flexible GnRh antagonist</arm_group_label>
    <arm_group_label>the progestin primed double stimulation group</arm_group_label>
    <other_name>Gynera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclo-Progynova</intervention_name>
    <description>Starting from cycle Day 3 of the intented cycle for thawed embryo transfer, patients will receive the white tablets of Cyclo-Progynova daily. From Day 10 onwards, endometrium growth will be monitored by transvaginal ultrasound.</description>
    <arm_group_label>the flexible GnRh antagonist</arm_group_label>
    <arm_group_label>the progestin primed double stimulation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>progesterone</intervention_name>
    <description>in the intended cycle of embryo transfer when endometrial thickness â‰¥ 7 mm. Progesterone administration (as 800 mg/day vaginal suppositories per day and 100 mg ampule IM every other day) will be continued until pregnancy testing 18 days after embryo transfer and in pregnant cases will continued till the 12 weeks of gestation.</description>
    <arm_group_label>the flexible GnRh antagonist</arm_group_label>
    <arm_group_label>the progestin primed double stimulation group</arm_group_label>
    <other_name>prontogest</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Indicated infertile women for ICSI of poor responders defined by Bologna criteria&#xD;
             either two or more of the following:(15) (i) advanced maternal age or any other risk&#xD;
             factor for POR. (ii) a previous POR ; less than 3-5 oocytes retrieved per cycle. (iii)&#xD;
             an abnormal ovarian reserve test (ORT): AFC less than 5-7 or AMH is less than 1.1&#xD;
             ng/ml.&#xD;
&#xD;
        Or two episodes of POR after maximal stimulation are sufficient to define a patient as poor&#xD;
        responder in the absence of advanced maternal age or abnormal ORT.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Male factor infertility due to azoospermia. 2. Patients with uncorrected uterine&#xD;
        pathology. 3. Patients with the diagnosis of severe endometriosis. 4. Patients with BMI&#xD;
        over 35.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aly A Hussein, Ass.lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Elshatby University hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherif S Gaafar, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Elshatby University hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aly A Hussein, Ass.lecturer</last_name>
    <phone>0020119448000</phone>
    <email>emam_aly@me.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Elshatby University Maternity Hospital</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Mascarenhas MN, Flaxman SR, Boerma T, Vanderpoel S, Stevens GA. National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. PLoS Med. 2012;9(12):e1001356. doi: 10.1371/journal.pmed.1001356. Epub 2012 Dec 18.</citation>
    <PMID>23271957</PMID>
  </reference>
  <reference>
    <citation>Briggs R, Kovacs G, MacLachlan V, Motteram C, Baker HW. Can you ever collect too many oocytes? Hum Reprod. 2015 Jan;30(1):81-7. doi: 10.1093/humrep/deu272. Epub 2014 Oct 31.</citation>
    <PMID>25362088</PMID>
  </reference>
  <reference>
    <citation>Drakopoulos P, Blockeel C, Stoop D, Camus M, de Vos M, Tournaye H, Polyzos NP. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? Hum Reprod. 2016 Feb;31(2):370-6. doi: 10.1093/humrep/dev316. Epub 2016 Jan 2.</citation>
    <PMID>26724797</PMID>
  </reference>
  <reference>
    <citation>Baerwald AR, Adams GP, Pierson RA. Ovarian antral folliculogenesis during the human menstrual cycle: a review. Hum Reprod Update. 2012 Jan-Feb;18(1):73-91. doi: 10.1093/humupd/dmr039. Epub 2011 Nov 8. Review.</citation>
    <PMID>22068695</PMID>
  </reference>
  <reference>
    <citation>Vanden Brink H, Chizen D, Hale G, Baerwald A. Age-related changes in major ovarian follicular wave dynamics during the human menstrual cycle. Menopause. 2013 Dec;20(12):1243-54. doi: 10.1097/GME.0b013e31828cfb62.</citation>
    <PMID>23571519</PMID>
  </reference>
  <reference>
    <citation>Kuang Y, Chen Q, Hong Q, Lyu Q, Ai A, Fu Y, Shoham Z. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reprod Biomed Online. 2014 Dec;29(6):684-91. doi: 10.1016/j.rbmo.2014.08.009. Epub 2014 Sep 6.</citation>
    <PMID>25444501</PMID>
  </reference>
  <reference>
    <citation>Zhang J. Luteal phase ovarian stimulation following oocyte retrieval: is it helpful for poor responders? Reprod Biol Endocrinol. 2015 Jul 25;13:76. doi: 10.1186/s12958-015-0076-2.</citation>
    <PMID>26209449</PMID>
  </reference>
  <reference>
    <citation>Liu C, Jiang H, Zhang W, Yin H. Double ovarian stimulation during the follicular and luteal phase in women â‰¥38 years: a retrospective case-control study. Reprod Biomed Online. 2017 Dec;35(6):678-684. doi: 10.1016/j.rbmo.2017.08.019. Epub 2017 Aug 24.</citation>
    <PMID>29030068</PMID>
  </reference>
  <reference>
    <citation>Zhang Q, Guo XM, Li Y. Implantation rates subsequent to the transfer of embryos produced at different phases during double stimulation of poor ovarian responders. Reprod Fertil Dev. 2017 Jun;29(6):1178-1183. doi: 10.1071/RD16020.</citation>
    <PMID>27166216</PMID>
  </reference>
  <reference>
    <citation>Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod. 2011 Jul;26(7):1768-74. doi: 10.1093/humrep/der106. Epub 2011 May 10.</citation>
    <PMID>21558332</PMID>
  </reference>
  <reference>
    <citation>Wang N, Wang Y, Chen Q, Dong J, Tian H, Fu Y, Ai A, Lyu Q, Kuang Y. Luteal-phase ovarian stimulation vs conventional ovarian stimulation in patients with normal ovarian reserve treated for IVF: a large retrospective cohort study. Clin Endocrinol (Oxf). 2016 May;84(5):720-8. doi: 10.1111/cen.12983. Epub 2015 Dec 21.</citation>
    <PMID>26603821</PMID>
  </reference>
  <reference>
    <citation>McNatty KP, Hillier SG, van den Boogaard AM, Trimbos-Kemper TC, Reichert LE Jr, van Hall EV. Follicular development during the luteal phase of the human menstrual cycle. J Clin Endocrinol Metab. 1983 May;56(5):1022-31.</citation>
    <PMID>6403567</PMID>
  </reference>
  <reference>
    <citation>Moffat R, Pirtea P, Gayet V, Wolf JP, Chapron C, de Ziegler D. Dual ovarian stimulation is a new viable option for enhancing the oocyte yield when the time for assisted reproductive technnology is limited. Reprod Biomed Online. 2014 Dec;29(6):659-61. doi: 10.1016/j.rbmo.2014.08.010. Epub 2014 Sep 4.</citation>
    <PMID>25311972</PMID>
  </reference>
  <reference>
    <citation>Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, Ai A, Shoham Z. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015 Jul;104(1):62-70.e3. doi: 10.1016/j.fertnstert.2015.03.022. Epub 2015 May 5.</citation>
    <PMID>25956370</PMID>
  </reference>
  <reference>
    <citation>Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L; ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011 Jul;26(7):1616-24. doi: 10.1093/humrep/der092. Epub 2011 Apr 19.</citation>
    <PMID>21505041</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 28, 2020</study_first_submitted>
  <study_first_submitted_qc>August 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>El Shatby University Hospital for Obstetrics and Gynecology</investigator_affiliation>
    <investigator_full_name>Aly Hussein</investigator_full_name>
    <investigator_title>Assistant lecturer, University of Alexandria</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Chorionic Gonadotropin</mesh_term>
    <mesh_term>Cetrorelix</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Dydrogesterone</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>November 1, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

